A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naive Adult Patients with Generalized Myasthenia Gravis

Administered By

Contributors

Start/End

  • June 18, 2019 - December 31, 2023